

RECEIVED

APR 05 2001

TECH CENTER 1600/2900

SHEET 1 OF 3



FORM PTO - 1449

ATTORNEY DOCKET NO.: MUR-003

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

APPLICANT(S): Farrar et al.

SERIAL NO.: 09/155,708

FILING DATE: October 2, 1998 GROUP: 1635

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>JK</i>	AA	5,087,617	02/11/92	Smith	514	44	02/15/89
<i>JK</i>	AB	5,246,921	09/21/93	Reddy et al.	514	44	08/05/92
<i>JK</i>	AC	5,399,346	03/21/95	Anderson et al.	424	93.21	03/30/94
<i>JK</i>	AD	5,582,972	12/10/96	Lima et al.	435	6	12/14/92
<i>JK</i>	AE	5,834,440	11/10/98	Goldenberg et al.	514	44	09/12/95
<i>JK</i>	AF	6,077,705	06/20/00	Duan et al.	435	320.01	05/14/97

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>JK</i>	BA	95/03335	02/02/95	WO					Y
<i>JK</i>	BB	97/11169	03/27/97	WO					Y
<i>JK</i>	BC	97/32024	09/04/97	WO					Y

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
<i>JK</i>	CA	Herrmann, "Cancer Gene Therapy: Principles, Problems, and Perspectives, <u>J. Mol. Med.</u> (1995) Vol. 73: 157-163.
<i>JK</i>	CB	Crooke, "Basic Principles of Antisense Therapeutics," <u>Antisense Research and Application</u> , pgs. 1-50.
EXAMINER	<i>Janet Lepp</i> DATE CONSIDERED 10-1-01	




RECEIVED

APR 05 2001

TECH CENTER 1600/2900

FORM PTO-1449		ATTORNEY DOCKET NO.: MUR-003	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Farrar et al.	
		SERIAL NO.: 09/155,708	
		FILING DATE: October 2, 1998 GROUP: 1635	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	CC	Branch, "A good antisense molecule is hard to find," <u>TIBS</u> 23, (1998), pgs. 45-50.	
	CD	Special News Report: "Gene Therapy's Growing Pains," <u>Science</u> (1995) Vol. 269, pgs. 1050-1055. <u>MARSHALL</u>	
	CE	Gomez-Navarro et al., "Gene Therapy for Cancer," <u>European Journal of Cancer</u> (1999) Vol. 35, No. 6, pgs. 867-885.	
	CF	Denman et al., "Ribozyme mediated degradation of β -amyloid peptide precursor mRNA in COS-7 cells," <u>Nucleic Acids Research</u> , Oxford University Press, (1994) Vol. 22, No. 12, pgs. 2375-2382.	
	CG	Lieber et al., "Adenovirus-Mediated Expression of Ribozymes in Mice," <u>Journal of Virology</u> (1996) Vol. 70, No. 5, pgs. 3153-3158.	
	CH	Kashani-Sabet et al., "Suppression of Neoplastic Phenotype <i>in Vivo</i> by an Anti- <i>ras</i> Ribozyme," <u>Cancer Research</u> (1994), Vol. 54, pgs. 900-902.	
	CI	Larsson et al., "Reduced β 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme," <u>Nucleic Acids Research</u> (1994) Vol. 22, No. 12, pgs. 2242-2248.	
	CJ	Khillan et al., "Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene," <u>Proc. Natl. Acad. Sci. USA</u> (1994) Vol. 91, pgs. 6298-6302.	
	CK	Ohkawa et al., "Ribozymes: From Mechanistic Studies to Applications <i>in Vivo</i> ," <u>J. Biochem.</u> (1995) Vol. 118, pgs. 251-258.	
	CL	Cotten et al. "Ribozyme mediated destruction of RNA <i>in vivo</i> ," <u>The EMBO Journal</u> (1989) Vol. 8, No. 12, pgs. 3861-3866.	
	CM	Kariko et al., "Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA," <u>FEBS Letter</u> (1994) Vol. 352, pgs. 41-44.	
	CN	Ohta et al., "Tissue-specific expression of an anti- <i>ras</i> ribozyme inhibits proliferation of human malignant melanoma cells," <u>Nucleic Acids Research</u> (1996) Vol. 24, No. 5, pgs. 938-942.	
	CO	Chowrira et al., " <i>In Vitro</i> and <i>in Vivo</i> Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-processing Ribozyme Cassettes," <u>The Journal of Biological Chemistry</u> (1994) Vol. 269, No. 41, pgs. 25856-25864.	
	CP	Little et al., "Generation of a Mammalian Cell Line Deficient in Glucose-regulated Protein Stress Induction through Targeted Ribozyme Driven by a Stress-inducible Promoter," <u>The Journal of Biological Chemistry</u> (1995) Vol. 270, No. 16, pgs. 9526-9534.	
EXAMINER		DATE CONSIDERED 10-1-01	



RECEIVED

APR 05 2001

SHEET 3 OF 3
TECH CENTER 1600/2900

FORM PTO/MAR 99 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MUR-003 APPLICANT(S): Farrar et al. SERIAL NO.: 09/155,708 FILING DATE: October 2, 1998 GROUP: 1635	
OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	CQ	Cameron et al., "Specific gene suppression by engineered ribozymes in monkey cells," <u>Proc. Natl. Acad. Sci. USA</u> (1989) Vol. 86, pgs. 9139-0143.	
	CR	Kobayashi et al., "Specificity of Ribozyme Designed for Mutated DHFR mRNA," <u>Biochemical Pharmacology</u> (1994) Vol. 47, No. 9, pgs. 1607-1613.	
	CS	Lieber et al., "Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library," <u>Molecular and Cellular Biology</u> (1995) Vol. 15, No. 1, pgs. 540-551.	
EXAMINER 		DATE CONSIDERED 10-1-01	

2043960